ReviewHuman vaccines & immunotherapeutics2012
Current evidence on intradermal influenza vaccines administered by Soluvia™ licensed micro injection system.
Review in Human vaccines & immunotherapeutics, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 2 syntheses or guidelines pooled it, 59 citations in OpenAlex.
- Recommended vaccinations for asplenic and hyposplenic adult patients.Human vaccines & immunotherapeutics · 2017Pooled it
- Immunogenicity of intramuscular MF59-adjuvanted and intradermal administered influenza enhanced vaccines in subjects aged over 60: A literature review.Human vaccines & immunotherapeutics · 2015Pooled it
- Assessing the integrity and mechanical properties of commercial microneedles: innovation or fad?Drug delivery and translational research · 2025Article
- The Major Role of T Regulatory Cells in the Efficiency of Vaccination in General and Immunocompromised Populations: A Review.Vaccines · 2024Review
- Microneedle-Mediated Immunization Promotes Lung CD8+ T-Cell Immunity.The Journal of investigative dermatology · 2023Article
- Emerging adjuvants for intradermal vaccination.International journal of pharmaceutics · 2023Review
- Innovative delivery systems for epicutaneous immunotherapy.Frontiers in immunology · 2023Review
- The role of nanoparticle format and route of administration on self-amplifying mRNA vaccine potency.Journal of controlled release : official journal of the Controlled Release Society · 2022Article
- Article
- Review
- Review
- Enhanced passive safety surveillance of three marketed influenza vaccines in the UK and the Republic of Ireland during the 2017/18 season.Human vaccines & immunotherapeutics · 2019Article
- Brief Exposure of Skin to Near-Infrared Laser Modulates Mast Cell Function and Augments the Immune Response.Journal of immunology (Baltimore, Md. : 1950) · 2018Article
- Fluzone® intra-dermal (Intanza®/Istivac® Intra-dermal): An updated overview.Human vaccines & immunotherapeutics · 2016Review
- Intradermal vaccination for infants and children.Human vaccines & immunotherapeutics · 2016Review
- Enhanced immune responses by skin vaccination with influenza subunit vaccine in young hosts.Vaccine · 2015Article
- Intradermal vaccination using the novel microneedle device MicronJet600: Past, present, and future.Human vaccines & immunotherapeutics · 2015Review
- Skin immunization with influenza vaccines.Current topics in microbiology and immunology · 2015Review
- Hepatitis B vaccine by intradermal route in non responder patients: an update.World journal of gastroenterology · 2014Review
- Assessment of acceptability and usability of new delivery prototype device for intradermal vaccination in healthy subjects.Human vaccines & immunotherapeutics · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Among the several strategies explored for (1) the enhancement of the immune response to influenza immunization, (2) the improvement of the vaccine acceptability and (3) the overcoming of the egg-dependency for vaccine production, intradermal administration of influenza vaccine emerges as a promising alternative to conventional intramuscular route, thanks to the recent availability of new delivery devices and the perception of advantages in terms of immunogenicity, safety, reduction of antigen content and acceptability. Data from clinical trials performed in children, adults < 60 y and elderly people and post-marketing surveillance demonstrate that actually, licensed intradermal influenza vaccines, Intanza™ 9 and 15 µg and Fluzone™ Intradermal, administered by the microinjection system Soluvia™, show an excellent acceptability, tolerability and safety profile. Formulations containing 9 and 15 μg per strain demonstrate, respectively, comparable and superior immunogenicity than conventional intramuscular vaccines. Licensed intradermal influenza vaccines can be considered a valid alternative to standard intramuscular vaccination offering significant advantages in low-responder populations and helping to increase influenza vaccination coverage rates especially in people with fear of needles or high apprehension associated with annual vaccination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.